UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase Erwinia chrysanthemi

Haematologica (Roma), 2023-10, Vol.108 (10), p.2606-2615

2023

Volltextzugriff (PDF)

Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL”

Technology in cancer research & treatment, 2021, Vol.20, p.15330338211049902-15330338211049902

Tong, Wing H.

2021

Volltextzugriff (PDF)

Comment on “Multiple reactions during desensitization may predict decreased efficacy of PEGasparaginase chemotherapy”

Annals of allergy, asthma, & immunology, 2024-10, Vol.133 (4), p.484-485

Tong, Wing H.

2024

Volltextzugriff (PDF)

Comment on: Desensitization using PEGasparaginase in the era of commercially available Erwinia: A single‐institution report on efficacy, cost, and resource utilization

Pediatric blood & cancer, 2024-05, Vol.71 (5), p.e30935-n/a

Tong, Wing H.

2024

Volltextzugriff (PDF)

Does anticoagulation prophylaxis reduce the rate of venous thromboembolism in adult acute lymphoblastic leukaemia treated with asparaginase‐based therapy?

British journal of haematology, 2022-04, Vol.197 (2), p.e24-e25

Tong, Wing H.

2022

Volltextzugriff (PDF)

The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia

Haematologica (Roma), 2014-11, Vol.99 (11), p.1716-1721

2014

Volltextzugriff (PDF)

Comment on: “Citrulline as a biomarker of bacteraemia during treatment for childhood acute lymphoblastic leukaemia”

Pediatric blood & cancer, 2022-03, Vol.69 (3), p.e29409-n/a

Tong, Wing H.

2022

Volltextzugriff (PDF)

Comment on “Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase”

Cancer chemotherapy and pharmacology, 2021-11, Vol.88 (5), p.919-920

Tong, Wing H.

2021

Volltextzugriff (PDF)

Comment on: Treatment‐induced cerebral sinus venous thrombosis in childhood acute lymphoblastic malignancies: New risk factors to consider

Pediatric blood & cancer, 2022-01, Vol.69 (1), p.e29297-n/a

Tong, Wing H.

2022

Volltextzugriff (PDF)

Comment on “Comparison of hypersensitivity rates to intravenous and intramuscular PEGasparaginase in children with acute lymphoblastic leukemia: A meta‐analysis and systematic review”

Pediatric blood & cancer, 2021-12, Vol.68 (12), p.e29250-n/a

Tong, Wing H.

2021

Volltextzugriff (PDF)

Comment on 'asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly diagnosed acute lymphoblastic leukemia'

Leukemia & lymphoma, 2022-01, Vol.63 (2), p.509-510

Tong, Wing H.

2022

Volltextzugriff (PDF)

Does L-asparaginase dose intensity correlate with acute pancreatitis in acute lymphoblastic leukemia patients?

Pediatric research, 2022-08, Vol.92 (2), p.341-342

2022

Volltextzugriff (PDF)

More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?

Journal of clinical oncology, 2023-05, Vol.41 (13), p.2450-2451

2023

Volltextzugriff (PDF)

Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy

Haematologica (Roma), 2013-05, Vol.98 (5), p.753-759

2013

Volltextzugriff (PDF)

Desensitization protocol should not be used in acute lymphoblastic leukemia patients with silent inactivation of PEGasparaginase

Haematologica (Roma), 2014-07, Vol.99 (7), p.e102-e104

2014

Volltextzugriff (PDF)

Comment on Association of FLT3 -internal duplication length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis

Haematologica (Roma), 2023-03, Vol.108 (3), p.926-927

2023

Volltextzugriff (PDF)

Comment on Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions

Journal of oncology pharmacy practice, 2021-06, Vol.27 (4), p.1054-1056

Tong, Wing H

2021

Volltextzugriff (PDF)

Comment on: Ocular abnormalities at diagnosis and after the completion of treatment in children and adolescents with newly diagnosed acute lymphoblastic leukemia

Pediatric blood & cancer, 2022-11, Vol.69 (11), p.e29700-n/a

2022

Volltextzugriff (PDF)

A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia

Blood, 2014-03, Vol.123 (13), p.2026-2033

2014

Volltextzugriff (PDF)

Are troponin T levels in women with pre-eclampsia related to development of pulmonary oedema?

European journal of obstetrics & gynecology and reproductive biology, 2023-03, Vol.282, p.168-169

2023

Volltextzugriff (PDF)

Comment on ‘risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy’

Journal of oncology pharmacy practice, 2023-04, Vol.29 (3), p.772-773

2023

Volltextzugriff (PDF)

Comment on: “Premedication prior to PEG‐asparaginase is cost effective in pediatric patients with acute lymphoblastic leukemia”

Pediatric blood & cancer, 2022-04, Vol.69 (4), p.e29474-n/a

2022

Volltextzugriff (PDF)

Independent factors associated with long-term functional outcomes in patients with a proximal femoral fracture: A systematic review

Experimental gerontology, 2020-10, Vol.139, p.111035-111035, Article 111035

2020

Volltextzugriff (PDF)

Native E. coli asparaginase upfront should be replaced by PEGasparaginase upfront in the treatment of pediatric patients with acute lymphoblastic leukemia

Hematological oncology, 2022-10, Vol.40 (4), p.809-811

2022

Volltextzugriff (PDF)

Disturbed CXCR4/CXCL12 axis in paediatric precursor B‐cell acute lymphoblastic leukaemia

British journal of haematology, 2014-07, Vol.166 (2), p.240-249

2014

Volltextzugriff (PDF)

1 – 25 von 237

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(214)
Mit Volltextzugriff
(215)

Publikationsform

Sprache

Englisch
(237)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase Erwinia chrysanthemi

Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL”

Comment on “Multiple reactions during desensitization may predict decreased efficacy of PEGasparaginase chemotherapy”

Comment on: Desensitization using PEGasparaginase in the era of commercially available Erwinia: A single‐institution report on efficacy, cost, and resource utilization

Does anticoagulation prophylaxis reduce the rate of venous thromboembolism in adult acute lymphoblastic leukaemia treated with asparaginase‐based therapy?

The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia

Comment on: “Citrulline as a biomarker of bacteraemia during treatment for childhood acute lymphoblastic leukaemia”

Comment on “Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase”

Comment on: Treatment‐induced cerebral sinus venous thrombosis in childhood acute lymphoblastic malignancies: New risk factors to consider

Comment on “Comparison of hypersensitivity rates to intravenous and intramuscular PEGasparaginase in children with acute lymphoblastic leukemia: A meta‐analysis and systematic review”

Comment on 'asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly diagnosed acute lymphoblastic leukemia'

Does L-asparaginase dose intensity correlate with acute pancreatitis in acute lymphoblastic leukemia patients?

More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?

Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy

Desensitization protocol should not be used in acute lymphoblastic leukemia patients with silent inactivation of PEGasparaginase

Comment on Association of FLT3 -internal duplication length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis

Comment on Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions

Comment on: Ocular abnormalities at diagnosis and after the completion of treatment in children and adolescents with newly diagnosed acute lymphoblastic leukemia

A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia

Are troponin T levels in women with pre-eclampsia related to development of pulmonary oedema?

Comment on ‘risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy’

Comment on: “Premedication prior to PEG‐asparaginase is cost effective in pediatric patients with acute lymphoblastic leukemia”

Independent factors associated with long-term functional outcomes in patients with a proximal femoral fracture: A systematic review

Native E. coli asparaginase upfront should be replaced by PEGasparaginase upfront in the treatment of pediatric patients with acute lymphoblastic leukemia

Disturbed CXCR4/CXCL12 axis in paediatric precursor B‐cell acute lymphoblastic leukaemia

Suchergebnisse filtern